Goodwill and Identifiable Assets

9 Months Ended

Sep. 30, 2014

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Identifiable Intangible Assets

Goodwill and Identifiable Intangible Assets. During the quarter ended March 31, 2014, the Company underwent a realignment resulting in a change in the Company's reportable segments. The goodwill related to the former Life Sciences segment has been allocated to the respective segments below based upon the relative fair value of each component of the former Life Sciences segment. All prior periods have been retrospectively restated to conform to the current presentation. See Note 13 Segment Reporting for further information.
The changes in the carrying amount of goodwill for the year ended December 31, 2013 and the nine months ended September 30, 2014 were as follows (in thousands):



	Apex			Oxford			Physician			Life Sciences Europe			Healthcare			Total
Balance as of December 31, 2012
Gross goodwill	$	289,712		$	150,619		$	51,561		$	3,753		$	122,230		$	617,875
Accumulated impairment	—			—			—			—			(121,717		)	(121,717		)
	289,712			150,619			51,561			3,753			513			496,158
Whitaker Acquisition (see Note 3)	—			—			7,452			—			—			7,452
CyberCoders Acquisition (see Note 3)	—			70,527			—			—			—			70,527
Divestiture - gross goodwill	—			—			—			—			(121,717		)	(121,717		)
Divestiture - accumulated impairment	—			—			—			—			121,717			121,717
Transfers	—			513			—			—			(513		)	—
Translation adjustment	—			—			—			811			—			811
Balance as of December 31, 2013
Gross goodwill	289,712			221,659			59,013			4,564			—			574,948
Accumulated impairment	—			—			—			—			—			—
	289,712			221,659			59,013			4,564			—			574,948
Acquisition accounting	—			796			(236		)	—			—			560
Translation adjustment	(1,210		)	(55		)	—			(220		)	—			(1,485		)
Balance as of September 30, 2014
Gross goodwill	288,502			222,400			58,777			4,344			—			574,023
Accumulated impairment	—			—			—			—			—			—
	$	288,502		$	222,400		$	58,777		$	4,344		$	—		$	574,023

As of the dates presented, the Company had the following acquired intangible assets (in thousands):



		As of September 30, 2014						As of December 31, 2013
	Estimated Useful Life	Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount
Intangible assets subject to amortization:
Customer relations	3 months – 10 years	$	109,872	$	53,764	$	56,108	$	110,007	$	41,564	$	68,443
Contractor relations	2 - 7 years	43,545		33,971		9,574		43,598		30,737		12,861
Non-compete agreements	2 - 7 years	3,828		1,855		1,973		3,863		1,424		2,439
In-use software	6 years	18,900		2,580		16,320		18,900		263		18,637
		176,145		92,170		83,975		176,368		73,988		102,380
Intangible assets not subject to amortization:
Trademarks		185,846		—		185,846		186,075		—		186,075
Goodwill		574,023		—		574,023		574,948		—		574,948
Total		$	936,014	$	92,170	$	843,844	$	937,391	$	73,988	$	863,403

Amortization expense for intangible assets with finite lives was $6.0 million and $5.2 million for the three months ended September 30, 2014 and 2013, respectively. Amortization expense for intangible assets with finite lives was $18.3 million and $15.9 million for the nine months ended September 30, 2014 and 2013, respectively. Estimated amortization for the remainder of this fiscal year, each of the next four fiscal years and thereafter follows (in thousands):



2014	$	6,079
2015	21,333
2016	17,726
2017	12,892
2018	10,310
Thereafter	15,635
	$	83,975

Goodwill and other intangible assets having an indefinite useful life are not amortized for financial statement purposes. Goodwill and intangible assets with indefinite lives are reviewed for impairment on an annual basis as of October 31 and whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. There were no triggering events that required an interim impairment analysis during the current period.

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References+ Details